Non-Fiction Books:

Pharmaceutical Safety Withdrawals

A Comparative Study of the United States and Canada

Format

Paperback

Customer rating

Click to share your rating 0 ratings (0.0/5.0 average) Thanks for your vote!

Share this product

Pharmaceutical Safety Withdrawals by Dominika Jegen
$77.99
In stock with supplier

The item is brand new and in-stock in with one of our preferred suppliers. The item will ship from the Mighty Ape warehouse within the timeframe shown below.

Usually ships within 10-14 days

Availability

Delivering to:

Estimated arrival:

  • Around 8-13 June using standard courier delivery

Description

In this sociohistorical case study, Dominika Jegen expands on this important body of work by utilizing international comparisons of regulatory data never before analyzed concurrently. She posits that these cases deserve to be investigated because their identification and contents reveal the nature of what users are not told, while also "opening up" new choices to be made about what users should be able to know. She also investigates why federal regulatory agencies on both sides of the border, although in possession of arguably the same evidence on pharmaceutical safety and adverse reactions for each pharmaceutical in question, made completely different decisions regarding the withdrawal of certain pharmaceuticals off the market. For example, pemoline's unfavourable risk-to-benefit ratio led to its withdrawal in Canada in 1999, while the Food and Drug Administration instead opted for two separate changes to the pemoline label before completely withdrawing the pharmaceutical in 2005. Although the approval of tolcapone came at relatively similar times in both countries, interestingly, withdrawal decisions once again differed owing to increasing concerns over reports of severe hepatotoxicity: Canada chose to withdraw the pharmaceutical within one year, while it is still available in the United States 10 years later. This study, although focused specifically on pemoline and tolcapone, poses new crucial questions about the intersection of science, treatment, and capital. On a deeper level of analysis, the cases of pemoline and tolcapone expose how the construction and dissemination of "facts" can be undertaken by corporations, particularly regarding scientific evidence submitted to reviewing bodies and for product monographs. Clearly, current safeguards towards unbiased medical information are lacking. Hence, funding may supply scientific support for a pharmaceutical which can then appease regulators and allow sales. The author raises the point that unfortunately this does not bode well for our society, and increasingly for other societies worldwide. This is an important book for those in public health and medical care.
Release date NZ
April 1st, 2009
Country of Publication
United States
Imprint
Teneo Press
Pages
179
Dimensions
140x216x11
ISBN-13
9781934844106
Product ID
2955030

Customer reviews

Nobody has reviewed this product yet. You could be the first!

Write a Review

Marketplace listings

There are no Marketplace listings available for this product currently.
Already own it? Create a free listing and pay just 9% commission when it sells!

Sell Yours Here

Help & options

  • If you think we've made a mistake or omitted details, please send us your feedback. Send Feedback
  • If you have a question or problem with this product, visit our Help section. Get Help
  • Seen a lower price for this product elsewhere? We'll do our best to beat it. Request a better price
Filed under...

Buy this and earn 456 Banana Points